First AI-assisted drug approved in China as AI virtual influencer ad rates top $28K
创业邦 · wechat · 2026-09-07
A roundup of Chinese AI industry news:
- First AI-assisted innovative drug approved: Xihu University's Eestevir hydrochloride tablet won conditional NMPA approval for treating mild-to-moderate COVID-19, the university's first fully in-house class-1 innovative drug.
- Virtual humans becoming a business: AI short-drama star Fang Taozi now charges 168K–258K RMB per ad, but a virtual brand endorsement claiming real wearing experience triggered regulatory investigation.
- AI short-drama prices collapsing: per-minute production rates fell from 5,000 RMB to a few hundred, while custom work still fetches 10K–20K; China's AI drama market is projected to top 40B RMB by 2026, with overseas reaching $4B.
- AI wealth boom: Altrata counts a record 3,795 billionaires in 2025; companies investing $30M+ in AI saw market caps rise 23% more than non-AI peers.
- Others: OpenAI's applied research lead says Astra ends human superiority in spatial reasoning; Shanghai launched an official anti-fraud AI app combining LLMs, multimodal models, and agents.
More from Companies & People
- Researcher calls undisclosed AI safety incident 'very bad,' disclosure excuse absurd — eliebakouch · 2026-09-07
- World's first math hackathon backed by Anthropic and OpenAI offers $2M compute over 40 hours — ColesThermoAI · 2026-09-07
- Clara Shih on when students should start using AI: once you can judge the output — clarashih · 2026-09-07
- Claude Code's Boris Cherny: don't optimize token cost, maximize returns — rohanpaul_ai · 2026-09-07
- OpenAI agent security engineer: alignment window is narrow, community must step up — Scobleizer · 2026-09-07
- RLSlow team credited with inventing RL at scale for LLMs — morqon · 2026-09-07